Loading
Efbemalenograstim alfa (Ryzneuta) is a once-per-cycle white cell booster, an alternative to pegfilgrastim, that reduces the risk of febrile infections after chemotherapy.
Efbemalenograstim alfa was approved by the FDA in November 2023 to decrease the incidence of infection manifested by febrile neutropenia in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy, and by the European Commission in March 2024 for reduction of the duration of neutropenia and incidence of febrile neutropenia after cytotoxic chemotherapy (excluding CML and MDS). Two phase 3 trials in breast cancer patients receiving docetaxel-cyclophosphamide showed a duration of severe neutropenia comparable to pegfilgrastim (GC-627-04) and superior to placebo (GC-627-05). Unlike pegylated G-CSF it uses Fc fusion rather than PEG for half-life extension. Bone pain, nausea and thrombocytopenia are the common adverse effects; it is not indicated for stem cell mobilisation.
Two G-CSF molecules fused to a human IgG2 Fc fragment; Fc-mediated recycling prolongs the half-life so that a single dose per chemotherapy cycle stimulates neutrophil production and release.
1.Efbemalenograstim alfa binds its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 2023 | Decrease in febrile neutropenia in adults with non-myeloid malignancies on myelosuppressive chemotherapy |
| EU | 2024 | Reduction in duration of neutropenia and febrile neutropenia after cytotoxic chemotherapy in adults (excluding CML and MDS) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Efbemalenograstim alfa" OR ABSTRACT:"Efbemalenograstim alfa" OR TITLE:"Ryzneuta" OR ABSTRACT:"Ryzneuta" OR TITLE:"F-627" OR ABSTRACT:"F-627") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Efbemalenograstim alfa, not a curated reading list.
Shares Pegfilgrastim, Growth factors: G-CSF and febrile neutropenia prevention and the tag supportive.
Shares Filgrastim (G-CSF) and the tag supportive.
Shares Growth factors: G-CSF and febrile neutropenia prevention and the tag supportive.
Shares Pegfilgrastim, Growth factors: G-CSF and febrile neutropenia prevention, Filgrastim (G-CSF).
Shares Pegfilgrastim, Filgrastim (G-CSF).
Shares Growth factors: G-CSF and febrile neutropenia prevention, Filgrastim (G-CSF).
Shares Pegfilgrastim, Growth factors: G-CSF and febrile neutropenia prevention.
Shares Pegfilgrastim, Filgrastim (G-CSF).